12:00 AM
Dec 17, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

PXVX0200: Phase I data

A placebo-controlled Phase I trial in 66 subjects showed that a single oral dose of PXVX0200 led to seroconversion to vibriocidal antibody in 80% of patients...

Read the full 110 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >